ISIS-SMNRx: Phase III started

Isis began the 15-month, double-blind, sham-controlled, international Phase III CHERISH trial to evaluate 12 mg intrathecal ISIS-SMNRx in about 120 non-ambulatory

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE